All In MedTech

FDA Clearance Tracker · P160042

REVANESSE ULTRA

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Aug 4, 2017 (this decision)Source: openFDAMethods & limitations

PMA

The decision

FDA number
P160042
Device name
REVANESSE ULTRA
Applicant location
Aurora
Received
Sep 22, 2016
Decided
Aug 4, 2017
Decision
Approved
Supplements
24 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code LMH

FDA's approval statement

As written in FDA's record.

Approval for the Revanesse Ultra. The device is indicated for injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults 22 years of age or more.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code LMH. The earliest in FDA's data is P800022, decided Jul 22, 1981.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Prollenium Medical Technologies, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.